Zamtocabtagene autoleucel, a tandem CD20–CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study

The Lancet Oncology · Elsevier

Аннотация

Publication date: November 2026 Source: The Lancet Oncology, Volume 27, Issue 11 Author(s): Peter Borchmann, Tom van Meerten, Gloria Iacoboni, Pierre Bories, Peter Dreger, Pim Mutsaers, László Gopcsa, Matthias Edinger, Lajos Gergely, Bastian von Tresckow, Peter Neumeister, Normann Steiner, Ulrich Jäger, Ana Triguero Moreno, Laimonas Griškevičius, François Lemonnier, Jaap van Doesum, Marie José Kersten, Jakob D Rudzki, Nirav N Shah

Читать у издателя →

Похожие статьи